Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis
Abstract Background and Aim Vedolizumab is a humanized monoclonal antibody that selectively inhibits the migration of gut‐homing memory T cells into the intestinal submucosa by antagonizing the interaction of α4β7 integrin with MAdCAM‐1. Vedolizumab is employed for ulcerative colitis with moderate t...
Guardat en:
| Autors principals: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2021-09-01
|
| Col·lecció: | JGH Open |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1002/jgh3.12630 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|